drugset / Trial / NCT00809783
Extension Study Of Tanezumab In Osteoarthritis
RandomizedParallel-groupDouble-blindTreatment
Summary
Safety extension study of Phase 3 Osteoarthritis trials with Tanezumab
Timeline
- Start
- 2009-02-06
- Primary completion
- 2010-11-02
- Completion
- 2011-06-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tanezumab | Monoclonal antibody | 2.5 mg | — |
| Subject | Tanezumab | Monoclonal antibody | 5 mg | — |
| Subject | Tanezumab | Monoclonal antibody | 10 mg | — |